Answers are grounded in this paper and cite their sources.
Breast cancer (BC) is the leading cause of cancer deaths in women. Patients with estrogen receptor-positive (ER + ) and human epidermal growth factor receptor 2-negative or low (HER2 - ; HER2 low ) BC exhibit a late recurrence pattern and resistance to endocrine therapy. Antibody-drug conjugates (ADCs) are new anticancer agents that currently show a remarkable acceleration in preclinical and clinical development. The aspartic protease cathepsin D (cath-D), a poor prognosis marker in BC, is a tumor cell-associated protein with pro-tumor activity that is highly and specifically secreted by BC cells. We recently showed using the human anti-cath-D antibody F1M1 that cath-D is a potent target for antibody-based therapy in BC. Here, we asked whether cath-D is a suitable target for ADC-based therapy in non-amplified ER + /HER2 low BC. To this aim, we bioconjugated F1M1 to the cytotoxic payload monomethyl auristatin F (MMAF) via a non-cleavable linker (for the release of a non-cell permeable MMAF metabolite) and to its cell permeable derivative monomethyl auristatin E (MMAE) via a protease-sensitive cleavable linker, to form the ADCs F1M1-MMAF and F1M1-MMAE respectively, with a drug-to-antibody ratio close to four. These F1M1-based ADCs were specifically internalized and showed cytotoxic activity in the nanomolar range in the ER + /HER2 low MCF-7 and endocrine therapy-resistant ER + /HER2 low MCF-7/LCC2 BC cell lines. In vivo , three injections of F1M1-based ADCs led to long-lasting tumor growth inhibition in mice harboring MCF-7/LCC2 cell xenografts. In conclusion, we showed for the first time that cath-D is a potent target for ADC in BC.
No takes yet. Share an insight, caveat, or question.
Nishimwe et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: